Why G Medicals news today may be bigger than it appears.

Israeli based G Medical [ASX: GMV] told the ASX today that it's been granted US FDA ‘Emergency Use Authorisation’ for one of its products because of shortages caused by US hospital system, overwhelmed by COVID-19 patients.

While there are nearly one and a half million Americans diagnosed with COVID-19, it is very difficult to get an accurate picture of how many people are actually in hospitals.

So just how many G Medical monitoring patches might be used is also unclear.

But more significantly, this will expose thousands of health care professionals working in America's six thousand hospitals to the G Medical technology.

The FDA authorisation means that G Medical's Vital Signs Monitoring System (“VSMS”) can be used when traditional ECG machines are not available.

The alternative technology is literally a patch that is placed on the patient. It is a clinical-grade 6 channel ECG monitor. Traditional monitors are 12 channels.

Emergency Use Authorisations are withdrawn once the crisis is over but this news means the G Medical brand and some of its tech, gets deep into the US medical market.

I interviewed CEO of G Medical a couple of weeks ago from Israel and thought it timely to re-post it.

ASX G Medical announcement key points:

• Patch now authorised in the USA for emergency use for patients undergoing treatment for COVID-19

• Patch entitled for reimbursement under US CPT code scheme – adds to GMV’s growing revenue profile

• Large addressable market for G Medical - ~1.5m confirmed cases of COVID-19 recorded in the US so far

• Fast route to market - manufacturing ramp-up of patch now underway at established facility in Israel ahead of future production at GMV's China production facility

• Patch will remotely monitor the QT syndrome prolongation on a patient’s electrocardiogram – all data will be compiled with extensive reports sent to healthcare professionals and GMV call centres for analysis